Trent Kamke Net Worth

The estimated Net Worth of Trent G Kamke is at least $5.58 Milión dollars as of 5 August 2024. Mr. Kamke owns over 182 units of Lemaitre Vascular Inc stock worth over $411,455 and over the last 18 years he sold LMAT stock worth over $4,693,005. In addition, he makes $471,894 as Senior Vice President - Operations at Lemaitre Vascular Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kamke LMAT stock SEC Form 4 insiders trading

Trent has made over 52 trades of the Lemaitre Vascular Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 182 units of LMAT stock worth $5,697 on 5 August 2024.

The largest trade he's ever made was exercising 18,865 units of Lemaitre Vascular Inc stock on 15 May 2015 worth over $56,595. On average, Trent trades about 1,897 units every 30 days since 2006. As of 5 August 2024 he still owns at least 4,743 units of Lemaitre Vascular Inc stock.

You can see the complete history of Mr. Kamke stock trades at the bottom of the page.

Trent Kamke biography

Trent G. Kamke serves as Senior Vice President - Operations of Lemaitre Vascular, Inc. Mr. Kamke joined us in 1997 as Quality Assurance Manager. From 1999 to 2005, Mr. Kamke served as our Vice President, Operations. Prior to joining us in 1997, Mr. Kamke was employed by Haemonetics Corporation, which designs, manufacturers, and markets automated blood processing equipment. Mr. Kamke received a B.A. in Physics from Colby College and a B.E. from the Thayer School of Engineering at Dartmouth College.

What is the salary of Trent Kamke?

As the Senior Vice President - Operations of Lemaitre Vascular Inc, the total compensation of Trent Kamke at Lemaitre Vascular Inc is $471,894. There are 4 executives at Lemaitre Vascular Inc getting paid more, with George LeMaitre having the highest compensation of $1,397,740.

How old is Trent Kamke?

Trent Kamke is 49, he's been the Senior Vice President - Operations of Lemaitre Vascular Inc since 2005. There are 15 older and 14 younger executives at Lemaitre Vascular Inc. The oldest executive at Lemaitre Vascular Inc is Dr. George D. LeMaitre, 87, who is the Founder and Chairman of Scientific Advisory Board.

What's Trent Kamke's mailing address?

Trent's mailing address filed with the SEC is 43 2nd Ave, Burlington, MA 01803, USA.

Insiders trading at Lemaitre Vascular Inc

Over the last 18 years, insiders at Lemaitre Vascular Inc have traded over $169,251,022 worth of Lemaitre Vascular Inc stock and bought 22,755 units worth $292,783 . The most active insiders traders include George W Le Maitre, Guido J Neels a David B Roberts. On average, Lemaitre Vascular Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,488,890. The most recent stock trade was executed by David B Roberts on 13 August 2024, trading 3,063 units of LMAT stock currently worth $107,236.

What does Lemaitre Vascular Inc do?

lemaitre vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. the company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. the company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. the company is listed on nasdaq.

Complete history of Mr. Kamke stock trades at Lemaitre Vascular Inc

Lemaitre Vascular Inc executives and stock owners

Lemaitre Vascular Inc executives and other stock owners filed with the SEC include:

• George LeMaitre,
  Chairman of the Board, Chief Executive Officer
• David Roberts,
  President, Director
• Joseph Pellegrino,
  Chief Financial Officer, Director
• George W. LeMaitre,
  Chairman & CEO
• Trent Kamke,
  Senior Vice President - Operations
• David B. Roberts,
  Pres & Director
• Joseph P. Pellegrino Jr.,
  CFO, Treasurer, Sec. & Director
• Trent G. Kamke,
  Sr. VP of Operations
• John O'Connor,
  Independent Director
• Lawrence Jasinski,
  Independent Director
• John Roush,
  Independent Director
• Bridget Ross,
  Independent Director
• James Russell,
  Director, Operations
• Helen Goulding,
  Director, Sales - Northern Europe
• Ryan Connelly,
  Vice President - Research & Development
• Xiang Zhang,
  Vice President, Regulatory Affairs
• Jacob Petersen,
  Vice President, Asia-Pac
• Jonathan Ngau,
  Vice President - Information Technology
• Roli Kumar-Choudhury,
  Vice President, Quality Affairs
• Kimberly Cieslak,
  Vice President - Marketing
• Chance Kriesel,
  Vice President - Sales, The Americas
• Giovannella Deiure,
  Vice President, Sales – Southern Europe
• Stephane Maier,
  Vice President, EMEA Operations
• Andrew Hodgkinson,
  Senior Vice President - Clinical, Regulatory and Quality Affairs
• Laurie Churchill,
  Senior Vice President, General Counsel
• Stephane Maier,
  Sr. VP of EMEA Operations
• Andrew Hodgkinson,
  Sr. VP of Clinical, Regulatory & Quality Affairs
• Daniel J. Mumford,
  Director of HR
• Kimberly L. Cieslak,
  VP of Marketing
• Laurie A. Churchill,
  Sr. VP & Gen. Counsel
• Dr. George D. LeMaitre,
  Founder and Chairman of Scientific Advisory Board
• Cornelia W Le Maitre,
  V.P., Human Resources,Director
• Michael T Wijas,
  VP of Sales, The Americas
• Michael H Thomas,
  Director
• Russell D Hays,
  Director
• Aaron M Grossman,
  General Counsel
• William N Jr Thorndike,
  Director
• Equity Investors Lp/Ma Hous...,
  
• George D Le Maitre,
  Director
• Michael C Jackson,
  Director
• Robert V Linden,
  VP, North American Sales
• Peter R Gebauer,
  President, International OP
• Kevin D Kelly,
  V. P. North American Sales
• Maik D Helmers,
  V.P. Central European Sales
• Guido J Neels,
  Director
• David N Gill,
  Director
• Duane M De Sisto,
  Director
• Martha Shadan,
  Director